Relay Therapeutics, Inc. (RLAY:NASDAQ) closed at $18.34 on October 22, 2026, down 0.38% on the day. The stock trades 13.8% below its 52-week high of $21.27 and 208.2% above its 52-week low of $5.95. Over the past year, it gained 184.1%. Relay Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 22, 2025, RLAY closed higher on 134 days (53%). Its best day was November 24, 2025 (+20.68%) and its worst was April 28, 2026 (-12.84%). The stock moved 10% or more in a single session 6 times. It opened at least 5% above the previous day's high 3 times.
Relay Therapeutics Inc is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3Ka mutant selective program, known as the RLY-PI3K1047 program. Its initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020.
Find more stocks like RLAY with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.